Viewing data from:

LAMIVUDINE AND ZIDOVUDINE

ANDA

LAMIVUDINE; ZIDOVUDINE | A079124 | HETERO LABS LTD UNIT III

1 strength0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$0.6918

per ea

Lowest NADAC/Unit

$0.6918

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
31722050660LAMIVUDINE-ZIDOVUDINE TABLET	$0.6918	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Apr 28, 2008	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 150MG;300MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Sep 17, 2015

No patent or exclusivity listings for this strength.